QRGenetics
Decoding the unknown

Revolutionizing Genetic Disease Treatment with GenAI

At QRGenetics, we're revolutionizing genetic disease treatment through the power of GenAI. Our system offers a groundbreaking approach to uncovering disease causes and targets, with applications extending to prevalent diseases, resulting in more effective treatments. Here's how we're making a difference:

Innovative Drug Discovery System

- Our cutting-edge system employs advanced ML/AI and LLM technology to deeply understand disease mechanisms and identify optimal treatments.
- We're expanding treatment options for common diseases by discovering new drugs in patients with rare genetic diseases and applying similar mechanisms to common ailments. This approach is invaluable to pharmaceutical companies seeking additional uses for their most profitable drugs.
- Moreover, we provide Pharma/Biotech companies an exclusive chance to broaden their product portfolios by uncovering new indications for their current drugs. Our proprietary target bank facilitates this, meticulously curated through thorough research into rare genetic diseases. This strategy not only presents a promising business proposition but also drives advancements in treatments for underserved medical areas, exemplified by our collaboration with SunPharma

Our Unique Solutions

- Solving rare genetic diseases not only benefits patients without other treatment options but also provides crucial insights for addressing more common diseases. Our emphasis on rare diseases carries commercial implications, with potential expansion into broader markets.

Achievements and Strategic R&D Initiatives

- With over 100 cases investigated to date, we've successfully pinpointed disease mechanisms and recommended drug treatments, significantly improving patients' lives and easing the burden on their families.
- Collaborating with Harvard University, MGB and Ichilov Hospital, we've progressed to clinical trials for a rare indication, showcasing patient condition improvements and advancing to FDA approval stages. Furthermore, we've identified similar disease mechanisms in cardiac-aortic aneurysm disease, demonstrating drug effectiveness and progressing to human trial phases in collaboration with Yale University.
- Our platform's adaptability allows us to address diverse genetic diseases, including neurological disorders, kidney diseases, obesity, and diabetes, highlighting the versatility of our research.
- Strategic collaborations, such as our partnership with SunPharma, underscore our commitment to making our system accessible to pharmaceutical companies, furthering our mission.

For more information on how we're revolutionizing treatment, visit us at qrgenetics.com.

QRGenetics Team

We are a dynamic blend of multidisciplinary team that combines expertise in computational biology, bioengineering, and pharmaceuticals to drive impactful research and development initiatives. a passion unites us for solving complex problems in genetic disease treatment.

Led by CEO Dr. Shane Wald-Altman, she brings a wealth of experience and expertise to the forefront of genetic disease treatment. Dekel Weiner, our VP of Data, spearheads the creation of robust datasets essential for our AI algorithms, Dr. Noa Beiloposki Head of Science, brings unparalleled expertise in computational biology and data analytics Dr. Karen Feldman, senior scientist contributing profound insights into molecular biology and drug discovery while Ilana Roitman, our Automated Specialist, contributes her expertise in bioengineering to streamline our processes. Robin Maslih, our LLM Specialist, harnesses the power of natural language processing to enhance our data analysis capabilities.

At QRGenetics, we're not just changing genetic disease treatment — we're shaping a healthier future.

For more information on how we're revolutionizing treatment, visit us at qrgenetics.com.